EFFICACY AND SAFETY IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION IN THE ENGAGE AF-TIMI 48 TRIAL
Once-daily LIXIANA® (edoxaban) demonstrated consistent efficacy vs well-managed warfarin in NVAF patients < 65, 65–74, and ≥ 75 years as well as very elderly patients ≥ 80 and ≥ 85 years.1
STROKE OR SYSTEMIC EMBOLISM
a Includes patients taking LIXIANA® 60 mg and those dose-reduced to 30 mg.
b Median time-in-therapeutic range (TTR): 67.2%, 68.4%, 69.6%, 69.5% and 68.4% for <65, 65–74, ≥75, ≥80 and ≥85 years, respectively.1
c Hazard ratio.
d Confidence interval.
Once-daily LIXIANA® (edoxaban) demonstrated consistently favourable safety vs well-managed warfarin in NVAF patients < 65, 65–74, and ≥ 75 years as well as very elderly patients ≥ 80 and ≥ 85 years.1
MAJOR BLEEDING
a Includes patients taking LIXIANA® 60 mg and those dose-reduced to 30 mg.
b Median time-in-therapeutic range (TTR): 67.2%, 68.4%, 69.6%, 69.5% and 68.4% for <65, 65–74, ≥75, ≥80 and ≥85 years, respectively.1
c Hazard ratio.
d Confidence interval.
The primary efficacy end point was a composite of all stroke or SEE. The principal safety end point was major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH) as (i) fatal bleeding; and/or (ii) symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome, and/or (iii) bleeding causing a fall in haemoglobin level of 2.0 g/dL or more, or leading to transfusion of two or more units of whole blood or red cells.2
